Education
About Us
Working with TipRanks
Follow Us
OncoSil Medical Ltd (AU:OSL)
ASX:OSL
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$13.46M
Enterprise ValueAU$7.89M
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding23,615,334
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Oncology Device PortfolioOncoSil’s focused medical device targeting locally advanced pancreatic cancer represents a specialized product-market fit with high clinical specificity. A durable niche in interventional oncology can create defensible clinical adoption pathways and partner opportunities that support long-term commercial traction.
Low Financial LeverageVery low debt levels reduce refinancing and interest burden risks, giving the company financial flexibility to fund clinical and commercial activities. This balance-sheet stability lengthens runway and lowers bankruptcy risk while management pursues commercialization and regulatory progress.
Positive Revenue Growth TrendSustained revenue expansion demonstrates improving market acceptance of the core product and early commercial traction. Continued top-line growth provides a platform to scale operations, absorb fixed costs and potentially move toward margin improvement if maintained over multiple quarters.
Bears Say
Persistent UnprofitabilityDeeply negative margins indicate the company is not yet able to monetize its offering at scale. Persistent operating losses erode shareholder equity, require ongoing funding, and limit reinvestment capacity, posing a multi-quarter structural challenge to achieving self-sustaining operations.
Negative Operating And Free Cash FlowContinued negative operating and free cash flows mean the business consumes cash to run and grow. This structural cash burn necessitates external financing or asset sales, constraining R&D and commercial expansion timing and increasing dilution or liquidity risk over the medium term.
Deeply Negative Return On EquityA deeply negative ROE signals the company is destroying shareholder capital rather than creating it. This long-term profitability deficiency undermines investor confidence, makes capital raises harder or more dilutive, and limits ability to fund growth without strategic change.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.56 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$13.46M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 167 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.242.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 23,615,334 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-385.20%
Trailing 12-Months
Asset Growth
6.40%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―